Retrospective Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. May 15, 2025; 17(5): 105027
Published online May 15, 2025. doi: 10.4251/wjgo.v17.i5.105027
Evaluation of efficacy and safety of targeted therapy and immune checkpoint inhibitors in metastatic colorectal cancer
Peng-Jian Wang, Jing Wang, Xue-Min Yao, Wei-Li Cheng, Lu Sun, Jie Yan, Yong-Ling Yu, Su-Yao Li, Da-Peng Li, Jing-Hao Jia
Peng-Jian Wang, Jie Yan, Clinical Medical School, North China University of Science and Technology, Tangshan 063000, Hebei Province, China
Jing Wang, Xue-Min Yao, Yong-Ling Yu, Su-Yao Li, Jing-Hao Jia, Department of Radiochemotherapy, North China University of Science and Technology Affiliated Hospital, Tangshan 063000, Hebei Province, China
Wei-Li Cheng, Da-Peng Li, Department of Digestive Oncology, Tianjin Tumor Hospital Qinhuangdao Hospital, Qinhuangdao 066000, Hebei Province, China
Lu Sun, Department of Radiochemotherapy, Tangshan People’s Hospital, Tangshan 063000, Hebei Province, China
Co-corresponding authors: Da-Peng Li and Jing-Hao Jia.
Author contributions: Li DP and Jia JH contribute equally to this study as co-corresponding authors; Wang PJ and Yan J contributed to patient screening, data collection, and statistical analysis; Wang J, Yao XM, Yu YL, and Li SY conceptualized and designed the study; Jia JH provided important inputs for statistical modeling and manuscript revision; Li DP directed the whole project and ensured funding; Cheng WL and Sun L ensured clinical coordination and compliance with ethical standards; the first draft was written by Wang PJ; Wang PJ, Wang J, Yao XM, Cheng WL, Sun L, Yan J, Yu YL, Li SY, Li DP, Jia JH participated in the review and editing of the manuscript.
Supported by Hebei Provincial Medical Science Research Project Program, No. 20240164.
Institutional review board statement: This investigation was approved by the Ethics Committee of the North China University of Science and Technology Affiliated Hospital (Approval No.202409300002).
Informed consent statement: The need for patient consent was waived due to the retrospective nature of the study.
Conflict-of-interest statement: The authors declare no conflicts of interest related to this manuscript.
Data sharing statement: No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Da-Peng Li, Chief Physician, Department of Digestive Oncology, Tianjin Tumor Hospital Qinhuangdao Hospital, No. 64 Guangming Road, Haigang District, Qinhuangdao 066000, Hebei Province, China. 15232330077@163.com
Received: January 9, 2025
Revised: March 7, 2025
Accepted: March 25, 2025
Published online: May 15, 2025
Processing time: 126 Days and 9.6 Hours
Core Tip

Core Tip: This study demonstrates that combining targeted therapy with immune checkpoint inhibitors significantly improves progression-free survival in patients with metastatic colorectal cancer (mCRC). The study also highlights the manageable safety profile of the combination therapy, offering a potential new approach for advanced mCRC treatment. Further research is needed to confirm these findings in larger trials.